Alkem Labs Acquires ₹300 Crore Stake in Subsidiary Enzene Biosciences
Alkem Laboratories acquired 64,02,018 equity shares in its subsidiary, Enzene Biosciences, for ₹299.99 crore. The acquisition aims to meet Enzene's capex and working capital needs. Enzene reported a turnover of ₹363.62 crore for FY25. Alkem's stake in Enzene increased to 99.61%.
The acquisition represents a substantial financial commitment and increases Alkem's control over a key subsidiary involved in the growing biosimilars sector, which could have a medium-term impact on the company's overall performance.
The acquisition of a significant stake in a subsidiary is a positive development, indicating investment and growth within the Alkem group.
Alkem Laboratories Limited has announced the acquisition of 64,02,018 equity shares in its subsidiary, Enzene Biosciences Limited, on a rights basis. The acquisition, priced at ₹468.60 per equity share, amounts to a total consideration of ₹299,99,85,634.80 (approximately ₹300 crore). The equity shares were allotted by Enzene on December 26, 2025.
Enzene Biosciences Limited, engaged in the research, development, manufacturing, and out-licensing of biosimilar products, as well as contract development and manufacturing for biosimilars and novel biologics, reported a turnover of ₹363.62 crore for the financial year ended March 31, 2025. This acquisition is intended to meet Enzene's capital expenditure and working capital requirements.
Following the allotment, Alkem Laboratories Limited's shareholding in Enzene Biosciences Limited has increased to 99.61% of the total equity share capital. The acquisition does not fall within the purview of related party transactions. Enzene Biosciences Limited was incorporated on August 28, 2006, and operates within the biosimilars and biologics contract manufacturing industry.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.